Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 10, 2016 4:27 AM ET

Pharmaceuticals

Company Overview of Ferring Holding SA

Company Overview

Ferring Holding SA, through its subsidiaries, develops, manufactures, and markets pharmaceutical products in the fields of reproductive health, urology, gastroenterology, endocrinology, and osteoarthritis. It offers MINIRIN for bedwetting in children and nocturia in adults; FIRMAGON for advanced hormone-dependent prostate cancer; and TESTIM for treating men suffering from low testosterone. The company also provides MENOPUR and BRAVELLE ovarian-stimulating treatments used in the preparation for in-vitro fertilization; TRACTOCILE to treat pre-term labor; ZOMACTON, a recombinant human growth hormone used to treat growth failure in children; PENTASA for the treatment of inflammatory bowel diseas...

Chemin de la Vergognausaz 50

Saint-Prex,  1162

Switzerland

Founded in 2000

Phone:

41 58 301 00 00

Fax:

41 58 301 00 10

Key Executives for Ferring Holding SA

Executive Chairman and Chief Executive Officer
Age: 64
Chief Financial Officer and Executive Vice President
Age: 58
President of the Executive Board and Chief Operating Officer
Age: 62
President of Ferring Pharmaceuticals Inc. and Chief Operating Officer of Ferring Pharmaceuticals Inc.
Vice Chairman
Compensation as of Fiscal Year 2015.

Ferring Holding SA Key Developments

Targeted Immuno Therapies and Ferring Sign IBD Treatment Collaboration Agreement

Ferring (Switzerland) and Targeted Immuno Therapies have entered into a strategic collaboration agreement whereby the Swiss firm received the global rights, with the exception of China, to the discovery of a novel treatment for inflammatory bowel diseases (IBD), with the parties set to collaborate on the development of a technology created by the Swedish firm. As per the agreement, Ferring would finance further product development and clinical trial programmes.

Similar Private Companies By Industry

Company Name Region
Abbott Products Operations AG Europe
Nycomed SICAR S.C.A. Europe
MSD Merck Sharp & Dohme A.G. Europe
Laboratoires Bailleul International SA Europe
EffRx Pharmaceuticals SA Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 28, 2015
Teva Women's Health, Inc., MILPROSA
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ferring Holding SA, please visit www.ferring.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.